Skip to content

Xeris Pharmaceuticals

US · XERS #2862 by market cap Listed 2018
16.97 +0.35 +2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

Price chart

Pre-market 16.69 +0.42%
After-hours 17.00 +0.18%
16.995.8916.972026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on XERS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +122.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 4.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 48.7x Better than 8%
Price / Sales 8.3x Better than 13%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 85.4% Better than 94%
Operating margin 8.5% Better than 46%
Net margin 0.2% Better than 27%
Return on equity -324.2% Better than 2%
Return on invested capital -17.5% Better than 14%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 95.1% Better than 100%
6-month return 174.2% Better than 100%
12-month return (ex latest month) 49.3% Better than 83%
Distance below 52-week high 1.8% Better than 98%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.2x Better than 60%
Debt to assets 67.3% Better than 6%
Interest coverage 1.0x Better than 29%
Free cash flow / net income 5,041.5% Better than 99%
Analyst View C

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target -2.8% Better than 2%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +1.86%
1M +52.47%
3M +97.33%
6M +172.39%
YTD +116.18%
1Y +148.10%
3Y +832.42%
5Y +647.58%

Key statistics

Price & volume

Prev close
16.62
Open
16.61
Day range
16.53 - 17.04
Avg price
16.82
Volume
2.86M
Turnover
48.05M
Amplitude
3.04%
52-week range
5.25 - 17.28

Valuation

P/E
5,656.67
P/E (TTM)
-628.52
P/B
63.56
EPS
0.00
Net profit
548.10K
Net assets
48.78M

Share structure

Market cap
3.10B
Float cap
3.00B
Shares out
182.70M
Float shares
176.52M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-06-21
52-week range 97% of range
5.25 17.28

1.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-37.15M net over the window

Short interest

Shares short
8.99M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Xeris Pharmaceuticals (XERS)?

Xeris Pharmaceuticals last traded at 16.97. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Xeris Pharmaceuticals's market cap?

About 3.10B.

What is the P/E ratio of Xeris Pharmaceuticals?

The trailing twelve-month P/E is -628.52, below its own 5-year average of 60.12 — toward the bottom of its historical range (0.08% percentile). See the Valuation tab for the full history.

Does Xeris Pharmaceuticals pay a dividend?

Xeris Pharmaceuticals does not currently pay a regular dividend.

Is Xeris Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.50, which implies 2.8% downside from the current price. This is not investment advice.

What is Xeris Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Xeris Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.

Xeris Pharmaceuticals discussion 0 comments

Add a comment